Latest news with #FinancialInstrumentsTradingAct
Yahoo
30-04-2025
- Business
- Yahoo
Changes in number of shares and votes in Essity
STOCKHOLM, April 30, 2025 /PRNewswire/ -- In accordance with the resolution at the Annual General Meeting on March 27, 2025, Essity has canceled 9,288,000 of its own shares of series B that the company previously repurchased. The total number of shares in Essity amounted on the date of this press release to 693,054,489, of which 58,973 654 Class A shares and 634,080,835 Class B shares. The total number of votes amounts to 1,223,817,375, of which the Class A shares correspond to 589,736,540 votes and the Class B shares correspond to 634,080,835 votes. NB: This information is such that Essity must disclose in accordance with the Financial Instruments Trading Act. The information was submitted for publication on April 30, 2025, at 08:00 CET. For further information, please contact:Karl Stoltz, Public Relations Director, +46 709 42 63 88, This information was brought to you by Cision The following files are available for download: Changes in number of shares and votes in Essity View original content: SOURCE Essity
Yahoo
31-01-2025
- Business
- Yahoo
Cantargia Announces Changes in Number of Shares and Votes
LUND, SWEDEN / / January 31, 2025 / Cantargia AB's (publ) ("Cantargia" or the "Company") (Nasdaq Stockholm:CANTA) today announced that the number of shares and votes in Cantargia AB (publ) has changed due to the recently completed rights issue (for further information, see the company's press release on December 23, 2024). Through the rights issue, the number of shares and votes in Cantargia increased by 64,924,971. Today, on the last trading day of the month, there are in total 248,611,655 shares and votes in Cantargia. For further information, please contactGöran Forsberg, CEOTelephone: +46 (0)46-275 62 60E-mail: This information is information that Cantargia is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-01-31 13:00 CET. About CantargiaCantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on hidradenitis suppurativa and systemic sclerosis. Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at AttachmentsCantargia announces changes in number of shares and votes SOURCE: Cantargia View the original press release on ACCESS Newswire Sign in to access your portfolio
